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Prostate cancer screening may detect nonprogressive cancers, leading to overdiagnosis and overtreatment. The potential for
overdiagnosis can be assessed from the reservoir of prostate cancer in autopsy studies that report incidental prostate cancer
rates in men who died of other causes. We aimed to estimate the age-specific incidental cancer prevalence from all published
autopsy studies. We identified eligible studies by searches of Medline and Embase, forward and backward citation searches
and contacting authors. We screened the titles and abstracts of all articles; checked the full-text articles for eligibility and
extracted clinical and pathology data using standardized forms. We extracted mean cancer prevalence, age-specific cancer
prevalence and validity measures and then pooled data from all studies using logistic regression models with random effects.
The 29 studies included in the review dated from 1948 to 2013. Incidental cancer was detected in all populations, with no
obvious time trends in prevalence. Prostate cancer prevalence increased with each decade of age, OR 5 1.7 (1.6–1.8), and
was higher in studies that used the Gleason score, OR 5 2.0 (1.1–3.7). No other factors were significantly predictive. The esti-
mated mean cancer prevalence increased in a nonlinear fashion from 5% (95% CI: 3–8%) at age <30 years to 59% (95% CI:
48–71%) by age >79 years. There was substantial variation between populations in estimated cancer prevalence. There is a
substantial reservoir of incidental prostate cancer which increases with age. The high risk of overdiagnosis limits the useful-
ness of prostate cancer screening.
Prostate cancer is a leading cause of death among men in
developed countries,1,2 and many urge that men should use the
prostate-specific antigen (PSA) test to screen for it. Screening
is now common in many countries,3–6 despite authoritative
recommendations that the benefits are outweighed by the
harms caused through overdiagnosis and consequent over-
treatment of disease that would not progress.7 If the PSA test is
positive (whatever the threshold selected), the next step is pros-
tate biopsy, which is performed with multiple biopsy needles
and histological examination to determine whether prostate
cancer is present, what grade and its extent. Diagnosis and
prognostic stratification is a difficult process, requiring subjec-
tive judgments that result in considerable variation between
pathologists.8,9 However, many cores are obtained, areas of
cancer may be missed, especially if small.
On the other hand, prostate cancers are identifiable in
some very young men and at an increasing rate with age,
suggesting that this cancer is usually a slowly developing dis-
ease with a long preclinical phase. Symptom development
and clinical diagnosis mostly occur in older men if at all:
many men with prostate cancer die of other causes, long
before any symptoms are clinically manifest.
This means biopsy has a high probability of finding pros-
tate cancers that would never have caused clinical disease,10
causing overdiagnosis,11,12 and because many are treated to
ensure that all cancers are treated, overtreatment. This is a
problem because of the high rates of adverse effects of treat-
ment (such as incontinence and impotence). Ideally, screen-
ing programs should only focus on the cancers that will
progress, not those that will be harmless.
To quantify the potential for overdiagnosis and overtreat-
ment, the reservoir of prostate cancer has to be defined. One
method of doing this comes from case series that report inci-
dental prostate cancer rates from autopsies of men who died
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of other causes. However, the limited sample sizes of each
series mean the estimates by ages are uncertain. Further, the
prevalence may vary by geography and race (because reported
incidence and mortality rates are low in Asian populations;
intermediate in men of European origin and high among black
Africans and African-Americans).13,14 Accordingly, we aimed
to combine all published autopsy series in adult men to obtain
an estimate of mean incidental prostate cancer prevalence by
age group, and how much this varies between populations.
Methods
Protocol and registration
The review protocol was not registered as there is no system-
atic review registry for prevalence studies.
Selection
We included autopsy studies of adult men (>age 18 years)
who had no history of preexisting prostate cancer and which
included a systematic histological examination of the prostate
gland. We excluded studies that did not report on age of the
men, did not methodically examine the prostate microscopi-
cally through step sectioning or were smaller than 100 men.
The principal outcomes were age-stratified rates of incidental
prostate cancer on histopathology.
Searching
We searched Medline and Embase using the terms listed in
Box 1, with no restrictions on year published, type of publica-
tion or language. To identify further papers for inclusion in
the review, we ran forward citation searches and checked the
references of all papers identified by the search for inclusion
in the review. We contacted authors to identify further studies.
Finally, we repeated our original search to identify any addi-
tional papers published during the period of data collection.
Box 1: Search strategy
1 Prostatic Neoplasms/
2 (prostat* adj3 (neoplasm* or neoplasia* or cancer* or carci-
noma* or adenocarcinoma* or tumour* or tumor* or malignan*
or pre-malignan* or premalignan*)).tw.
3 Autopsy/
4 (autops* or postmortem* or post-mortem* or post mortem*).tw.
5 (#1 or #2) AND (#3 or 4)
Validity assessment
We planned a priori subgroup analysis for the following risk
of bias study characteristics: consecutive versus nonconsecu-
tive case selection, population-based versus hospital-based
studies and majority of cancers reported high-grade (Gleason
score >6; this threshold has important treatment implica-
tions). We also planned subgroup analysis of the following
pathology validity characteristics: thoroughness of examina-
tion (interval between sections), Gleason score used, possible
delay in performing autopsy <72 hr, peer review of diagno-
sis, immunohistochemical stains used to confirm diagnosis
and perineural spread noted in any of the cancers (a feature
of prostate cancer).
Study selection and data abstraction
Two authors (CD and PG or JD) checked the titles and
abstracts of all potentially relevant English articles, and the
full text of these was obtained. One author (CD) reviewed
titles and abstracts of all non-English articles with the help of
researchers expert in the language in question. Two authors
(KB and JD or PG) independently checked all the full-text
articles for eligibility. Disagreements were resolved through
discussion with a third author (CD).
Two authors independently extracted clinical data (KB
and CD) and pathology data (GW and KB) using standar-
dized forms. Disagreements were decided by a third author
(PG or CD). We extracted data on mean cancer prevalence,
decade-specific cancer prevalence and the validity measures
as described above. When data were not available elsewhere
in the paper, we extracted data from figures using Plot digit-
izer software (http://plotdigitizer.sourceforge.net, accessed
August 18, 2014).
Quantitative data synthesis
Our main summary measure was the prevalence of previously
undiagnosed prostate cancer. We pooled data from all studies
using logistic regression models with random intercepts to
represent the distribution of underlying cancer prevalences
between different populations. This type of model also
allowed for the nested structure of the data, with decade-
specific prevalence estimates nested within each study. We
used the model to examine the impact of the validity charac-
teristics on the estimates of age-adjusted prevalence. SAS 9.3
was used for all analyses. The NLMIXED procedure was used
to build the models, as has been recommended.15
What’s new?
Before symptoms of prostate cancer manifest clinically, many men die of other causes. Yet, prostate screening, particularly in
older men, frequently turns out positive, resulting in overdiagnosis and overtreatment. This meta-analysis of published
autopsy studies shows that incidental prostate cancer increases with age and with the use of sensitive screening strategies,
especially in older men. Among men whose prostate cancers are designated “favorable-risk,”ô active surveillance and subse-
quent biopsy can result in reclassification with higher-grade cancer, purely by chance. The potential for the detection of clini-
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Results
The selection of studies is summarized in Figure 1: 1,822
abstracts were identified by Medline and Embase searches
and 117 papers were retrieved for full-text review. A further
2,334 papers were identified from the references of these
papers, and from forward citation searches of them 91 were
retrieved, giving a total of 208 papers that had full-text
review. We assessed 129 of these as not meeting our selection
criteria. Several of the remaining 76 studies used overlapping
data. We contacted authors to resolve some potential over-
laps, but, when uncertainty remained, we were conservative,
excluding 47 studies that might potentially overlap with
others, to avoid the risk of double counting cases. For each
set of potentially overlapping reports, we chose the one that
reported on the largest number of men, in the most detail
(this was usually the most recent report). This left 29 stud-
ies16–44 to be included in the systematic review (Table 1).
Figure 2 shows the overall prevalence of incidental pros-
tate cancer for the studies by year of publication, with size of
data points proportional to the number of men in the study.
There was no visible trend in estimated prevalence over time
from the earliest study, published in 1948 to the most recent
study, published in 2013 (we formally test for temporal trend
in the age-adjusted model below). Studies performed in ear-
lier Japanese populations gave lower prevalence but more
recent studies were not different from those in European-
origin populations (there was one outlier Asian study per-
formed on Chinese). There were insufficient data to compare
the cancer prevalence in men of African descent to that of
other ethnicities.
Data in 25 studies allowed age-specific prevalence calcula-
tions thus allowing estimates of changes in cancer prevalence
with age (summarized in Fig. 3 and the Supporting Informa-
tion Appendix Figure). Four studies33,36,42,44 were excluded as
prevalence per decade of age could not be calculated.
Data from 22 studies on the number of men and the
number of cases per decade of age available were included in
the model analysis. Three studies18,19,30 in Figure 3 only
reported cancer prevalence per decade so could not be
included in the model without specific number of cancers
and number of men per decade of age. One study had data
for all the seven age groups, a further five studies, nine stud-
ies, six studies and one study had data for six, five, four and
three age groups, respectively. In total, 109 observations were
used in the baseline model. There was very strong evidence
that cancer prevalence differed between studies (test for ran-
dom intercepts, p< 0.001). Prostate cancer prevalence
increased with each decade of age (p< 0.001) and this
increase was similar for all studies (test for random decade
slope, p5 1.0). We tested other available validity characteris-
tics in the random intercepts model (adjusted for decade of
age, Table 2). We found no evidence that population versus
hospital based; section thickness; peer review; reporting of
perineural spread or possible autolysis affected cancer preva-
lence, after allowing for the increase in prevalence with age.
We also found no statistical evidence that use of immunohis-
tochemical stain or having the majority of cancers with a
Gleason score >6 had effects on cancer prevalence, although
the confidence intervals for these were both wide reflecting
the fact that only four studies used immunohistochemical
stains and only one study had majority of cancers with a
Gleason score >6. However, there was evidence that studies
using the Gleason score reported higher prevalence than
those that did not (OR: 2.03) so this was included in the final
model. Finally, we found no evidence for a temporal trend in
age-adjusted prevalence among the studies overall (p5 0.11)
or among those published before 1985 (p5 0.13) or after this
date (p5 0.75).
We used the baseline model to estimate the unadjusted
mean age-specific prevalence for the different populations
(Fig. 3, dashed line). The estimated mean prevalence at age
<30 years was 4%; this increased to 49% by age >79 years.
The final model adjusted the estimates of studies that did not
use Gleason score upwards (Fig. 3, solid line). The estimated
mean cancer prevalence at age<30 years was 5% (95% CI: 3–
8%); this increased similarly in a nonlinear fashion to 59%
(95% CI: 48–71%) by age >79 years. There was substantial
variation between populations in estimated cancer prevalence;
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for example, the 5th, 50th and 95th percentile of cancer prev-
alence for age <30 years were 2, 5 and 17%, respectively. At
age 40–50 years they were 5, 15 and 37%, and at age >79
years 30, 59 and 84%, respectively.
Discussion
We identified 29 studies in more than 20 countries spanning
over six decades, which consistently demonstrated a high
prevalence of prostate cancer as an incidental finding at
autopsy. As expected, the prevalence is most strongly related
to age, with the prevalence doubling about every 14 years.
Age only explains part of the considerable variation between
studies: we could identify only one other clear factor: use of
a Gleason score. The studies not using the Gleason grading
systems for tumors (dominated by older studies, in western
countries) appear to have used conservative criteria for
tumor diagnosis, which might explain the lower prevalences.
The several other potential factors that might have been
predictive (population selection, prostate sampling method
and staining technique) were not significant in our model.
This may be partly a consequence of incomplete descrip-
tions of methods and the limited statistical power to detect
an effect (e.g., few studies used immunohistochemical
stains). There may be real differences in cancer prevalence
between different populations not accounted for by
Figure 2. Prevalence of incidental prostate cancer in studies by year of publication.
Figure 3. Decade-specific prevalence of: (i) incidental prostate can-
cer from studies and (ii) mean prevalence from models before and
after adjustment for use of Gleason score 294 3 188 mm (100 3
100 DPI).
Table 2. Estimates of odds ratio (from logistic regression model) for
11 possible predictive factors including decade of age




IHC stain used 3.38 (0.75–15.31) 0.11
Population vs. hospital based 0.78 (0.40–1.53) 0.48




Peer review 1.51 (0.73–3.11) 0.25
Perineural spread noted 0.49 (0.26–1.17) 0.11
Gleason score used 2.03 (1.12–3.70) 0.02
Majority had GS>6 1.07 (0.07–15.74) 0.75
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differences in the way the studies were done. For example,
the prevalence of incidental tumors was relatively low in
earlier studies of Japanese men, although more recent study
estimates are similar to the rest of the world. Other genetic
and cultural differences between populations may result in
variation in cancer prevalence, but could not be demon-
strated in this review.
Our comprehensive search with no language restrictions
yielded a considerable number of studies over several decades.
The age-adjusted rates of incidental cancer appear to have
remained fairly constant over time. This contrasts with the
rates of cancer detected during men’s lifetimes in many devel-
oped countries where the age-adjusted incidence rates dramati-
cally increased after widespread PSA testing, after a slower
increase which coincided with increasing use of transurethral
resection of the prostate.45 Whether there has been any
increase in the cancers which would progress if untreated
remains uncertain; our data suggest that the reservoir of can-
cers that do not progress has remained more or less the same.
Our study has several limitations, principally the unknown
validity of pathological assessment at autopsy. Autolysis has
the potential to mimic cancer and might falsely elevate esti-
mates of cancer prevalence. We attempted to test for this by
separately analyzing studies with strict inclusion criteria
based on minimal delay between death and autopsy, which
actually yielded higher cancer prevalences than the remain-
der. The studies that used pathology practices similar to
those currently used in the evaluation of surgical prostate
specimens (such as Gleason score, immunohistochemical
stain and peer review) also had higher estimates of cancer
prevalence than those that did not. Although there was a
high proportion of Gleason score 6 in earlier U.S. series,
there is evidence to suggest a “grade creep” over time such
that many of these cancers would now be graded as Gleason
score >6.45 The one study with majority Gleason score >6
had similar prevalence estimates to those with majority 6.
Taken together, these findings suggest that our estimates are
a true indication of the incidental cancer reservoir rather
than mere artifact. Further, if a biopsy of these cancers had
been done ante-mortem and assessed using current pathology
practices, it appears likely that many would have been classi-
fied as high grade and active treatment recommended.
Another limitation was missing details of methods and
prevalence of cancer stratified by age and other factors; as
many studies were old, contact with authors for clarifications
was not possible. Insufficient data meant we were unable to
test for differences in prevalence by geography and race. In
particular, our sensitive search strategy failed to identify any
studies solely in men of African descent that met our inclu-
sion criteria. Fewer than half of the studies were published
after 1986 when PSA testing began, and most were in coun-
tries where screening was uncommon. In populations where
screening has become common this may have lead to under-
estimation of incidental cancer prevalence among autopsy
series that exclude diagnosed men, although the effects are
unlikely to be large.23 Cancers that present clinically will also
add to total cancer prevalence in the population, but these
are much less common than incidental cancers (A man in
the United States has 10% lifetime risk of symptomatic dis-
ease and 3% chance of dying from prostate cancer).46 Clinical
cancers are not the focus of this paper which seeks to esti-
mate the full potential for overdiagnosis when screening for
(clinically silent) incidental prostate cancer.
Our findings are in keeping with those of a previous report
that included eight autopsy studies46 and a very recent review
that included 56 studies, 24 of which used step sectioning.14
Some of the studies included in these reviews were excluded
from our final selection because there were <100 men or
another reason as outlined in Figure 1. Despite differences in
the methods used for our review and each of these, the esti-
mated mean age-specific prevalences are broadly similar. The
recent review examined age-specific prevalence according to
race and found differences between men of Asian (lowest prev-
alence), European (middle) and African descent (highest prev-
alence); it was not reported if these were statistically
significant.14 The method used to arrive at these estimates may
have been flawed; although race was defined on subsets of men
within the studies, the estimates of age-specific prevalence
according to race were arrived at by comparison between stud-
ies. Differences in the way the studies were conducted, such as
the method of pathological examination, may have confounded
the apparent effects of race on cancer prevalence. Indeed, the
age-specific rates for different races within the individual stud-
ies appear much more similar.
Our review, which uses data only from large high-quality
primary studies, corroborates the overall age-specific preva-
lence estimates of the other reviews. Importantly, we also
show that although there is substantial variation between
study populations, much of this may be due to methodologi-
cal differences. The more carefully we look for prostate can-
cer, the more likely we are to find it: evaluating using the
Gleason score grading system more than doubled the odds of
finding cancer; and although not statistically significant, we
estimated that use of a specific immunohistochemical stain to
aid diagnosis raised the odds by over three times. Taken
together, these data suggest that our findings are conservative
estimates and the true incidental cancer prevalence rates may
be even higher. This reinforces the maxim that “any excuse
to biopsy the prostate has an excellent, age-dependent chance
of being positive.10” This is now more true than ever, as
recent pathology practices (such as those we examined)
increase the probability of making a diagnosis of cancer.
The age-specific prevalences demonstrate that screening
will cause overdetection. Other methods for estimating the
incidence of overdetection have been reported. In the large
European Trial of PSA screening men aged 55–69 years
(ERSPC), after 13 years follow-up 8% of the screened group
had prostate cancer detected (compared to 6% of the con-
trols).47 Our estimates for men aged 60–70 and aged 70–80
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undergoing regular screening. This may reflect the modest
sensitivity of PSA to detect cancers, and particularly the
probability of even multiple needle biopsies missing a small
focus. It suggests that a residual pool of undetected “cancers”
is likely, even in intensively screened populations, though the
proportion of these that would progress and invade is likely
to be much smaller.
There are several clinical implications of these autopsy
studies. First is the obvious risk of overdetection during pros-
tate cancer screening. A more sensitive test than PSA, or a
lower threshold, and more intense biopsy sampling will
increase overdetection. Second, the rate of overdetection will
increase with age. Third, the high rates from the study where
the majority of incidental cancers were Gleason score >623
suggests that men with “favorable-risk cancer” who enter
active surveillance have a substantial probability of higher
grade cancer being found at a subsequent biopsy, purely due
to chance sampling.
Despite these high prevalences of histological findings, few
prostate cancers present within men’s lifetime if not discov-
ered by screening, and even in intensely screened populations
most are left undiscovered. Hence, a key research implication
is the urgency of finding better methods of distinguishing
progressive from indolent prostate cancers.48 Future autopsy
studies should address validity characteristics identified in
this review so that estimates are unbiased and reflect the full
extent of the latent cancer reservoir for each age group in the
population. They should seek to explain real differences in
the frequency of latent cancer by examining and reporting
other predictors such as race, geography and family history.
Studies are needed in diverse settings, including African and
other understudied populations, so that country-specific data
may inform local policy decisions on the potential for over-
diagnosis with screening.
In conclusion, we found a universal reservoir of latent
prostate cancer that increases with age. Proponents of pros-
tate cancer screening need to be wary of the high risk of
overdiagnosis.
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